George Scangos (via Getty Images)
October 6, 2020 09:15 AM EDTUpdated 10:38 AM
R&D
Coronavirus

GSK, Vir cleared to leap in­to PhI­II, an­gling for a spot in the Covid-19 an­ti­body race led by Lil­ly, Re­gen­eron

Amber Tong

Six months af­ter Glax­o­SmithK­line paid $250 mil­lion for a stake in Vir Biotech­nol­o­gy and a seat at the ta­ble de­vel­op­ing an­ti­bod­ies against Covid-19, it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times